WO2018192590A3 - 一种稳定的口服药物组合物及其制备方法 - Google Patents
一种稳定的口服药物组合物及其制备方法 Download PDFInfo
- Publication number
- WO2018192590A3 WO2018192590A3 PCT/CN2018/091940 CN2018091940W WO2018192590A3 WO 2018192590 A3 WO2018192590 A3 WO 2018192590A3 CN 2018091940 W CN2018091940 W CN 2018091940W WO 2018192590 A3 WO2018192590 A3 WO 2018192590A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- pharmaceutical composition
- pharmaceutically acceptable
- method therefor
- oral pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种稳定的口服药物组合物及其制备方法。所述组合物中含有一有效量的结构如式(Ⅰ)所示的化合物或其药学上可接受的盐和药学上可接受的载体,所述药学上可接受的载体中包括熔点或玻璃化转变温度或软化温度在180℃以下的聚合物,并且所述聚合物与结构如式Ⅰ所示的化合物或其药学上可接受的盐的质量比在1以上。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710264635.6A CN107007559B (zh) | 2017-04-21 | 2017-04-21 | 一种稳定的口服药物组合物及其制备方法 |
| CN201710264635.6 | 2017-04-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2018192590A2 WO2018192590A2 (zh) | 2018-10-25 |
| WO2018192590A3 true WO2018192590A3 (zh) | 2018-12-20 |
Family
ID=59446978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2018/091940 Ceased WO2018192590A2 (zh) | 2017-04-21 | 2018-06-20 | 一种稳定的口服药物组合物及其制备方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN107007559B (zh) |
| WO (1) | WO2018192590A2 (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1230883A (zh) * | 1996-09-24 | 1999-10-06 | 伊莱利利公司 | 包衣颗粒制剂 |
| CN1178662C (zh) * | 1995-03-24 | 2004-12-08 | 伊莱利利公司 | 2-甲基-噻吩并-苯并二氮杂�口服制剂 |
| CN101189001A (zh) * | 2005-02-15 | 2008-05-28 | 伊兰制药国际有限公司 | 纳米微粒苯并二氮杂䓬气雾剂及注射剂 |
| CN101827597A (zh) * | 2007-08-20 | 2010-09-08 | 伊沃泰克神经科学有限责任公司 | 睡眠障碍的治疗 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2372040C (en) * | 1999-05-12 | 2008-12-02 | Francois Jenck | Imidazodiazepine derivative |
| US20090054412A1 (en) * | 2007-08-20 | 2009-02-26 | John Alan Kemp | Treatment of Sleep Disorders |
-
2017
- 2017-04-21 CN CN201710264635.6A patent/CN107007559B/zh active Active
-
2018
- 2018-06-20 WO PCT/CN2018/091940 patent/WO2018192590A2/zh not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1178662C (zh) * | 1995-03-24 | 2004-12-08 | 伊莱利利公司 | 2-甲基-噻吩并-苯并二氮杂�口服制剂 |
| CN1230883A (zh) * | 1996-09-24 | 1999-10-06 | 伊莱利利公司 | 包衣颗粒制剂 |
| CN101189001A (zh) * | 2005-02-15 | 2008-05-28 | 伊兰制药国际有限公司 | 纳米微粒苯并二氮杂䓬气雾剂及注射剂 |
| CN101827597A (zh) * | 2007-08-20 | 2010-09-08 | 伊沃泰克神经科学有限责任公司 | 睡眠障碍的治疗 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018192590A2 (zh) | 2018-10-25 |
| CN107007559B (zh) | 2020-05-15 |
| CN107007559A (zh) | 2017-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4512399A3 (en) | Solid state forms of tafamidis and salts thereof | |
| WO2014209841A3 (en) | Compounds for treating spinal muscular atrophy | |
| WO2012021715A3 (en) | Stable formulations of linaclotide | |
| BR112013025519A2 (pt) | composição farmacêutica | |
| WO2019043634A3 (en) | CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS | |
| HK1248069A1 (zh) | 去乙酰氧基微管溶素h及其类似物 | |
| WO2018192910A3 (en) | Process for making an anti-soiling coating composition and a coating made therefrom | |
| WO2017015433A3 (en) | Compound targeting il-23a and b-cell activating factor (baff) and uses thereof | |
| WO2014203275A3 (en) | An improved process for the preparation of apixaban and intermediates thereof | |
| WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
| HK1217295A1 (zh) | 4'-疊氮基,3'-脫氧基-3'-氟取代的核苷衍生物 | |
| EP4295916A3 (en) | Salts of 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and crystalline forms thereof | |
| EA200702589A1 (ru) | 2,6-хинолинильные производные, способы их получения и их применение | |
| IL280376A (en) | The history of boronic acid, its preparation and pharmaceutical preparations containing it | |
| PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
| EP3792253A4 (en) | COMPOUND OF NOVEL STRUCTURE, COMPLEX, PHARMACEUTICAL COMPOSITION ANTI-CANCER AND ANTI-CANCER DRUG CONTAINING THEM | |
| WO2012108631A3 (en) | Pharmaceutical compositions comprising revaprazan-containing nanoparticles and processes for the preparation thereof | |
| WO2015002755A3 (en) | Compounds for the treatment of malaria | |
| WO2012029074A3 (en) | Pharmaceutical compositions of linezolid | |
| EP2497464A3 (en) | Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture | |
| CR20210173A (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| WO2016137862A3 (en) | Electrical tracking resistance compositions, articles formed therefrom, and methods of manufacture thereof | |
| WO2018192590A3 (zh) | 一种稳定的口服药物组合物及其制备方法 | |
| WO2011112793A3 (en) | Non-aqueous structured compositions | |
| EP4251579A4 (en) | GLASS COMPOSITIONS WITH HIGH POISSON NUMBER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18787390 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18787390 Country of ref document: EP Kind code of ref document: A2 |